Global Hemorrhoid Drugs Market Insights Forecasts to 2033

• The Market Size is Expected to Grow at a CAGR of around 4.21% from 2023 to 2033
• The Worldwide Hemorrhoid Drugs Market Size is Expected to Hold a Significant Share by 2033
• Asia Pacific is predicted to grow at the fastest CAGR throughout the projection period

The Global Hemorrhoid Drugs Market Size is anticipated to hold a significant share by 2033, growing at a CAGR of 4.21% from 2023 to 2033. The market expansion is attributed to the sedentary lifestyle including eating fast foods, a high intake of food that increases body heat, a low-fiber diet, obesity, lack of exercise, and advancements in technology.

Market Overview

The market for hemorrhoid drugs constitutes the drug development phase, production, and distribution of drugs that are used in the management of hemorrhoids. Hemorrhoids, or piles, are swollen veins in the lower anus and rectum, irritating due to age, pregnancy, and constipation. It includes two types such as internal hemorrhoids often invisible, can cause painless bleeding during bowel movements or a prolapsed hemorrhoid pushing through the anal opening, causing discomfort and irritation during stool passage while external hemorrhoids, located under the skin around the anus, can cause itching, pain, swelling, and bleeding.

The National Library of Medicine reported that hemorrhoid disease is the fourth leading outpatient gastrointestinal diagnosis in the US, with a global prevalence of 4.4%. Australia has the highest prevalence at 38.93%, followed by Israel, Korea, Africa, and Egypt. The rising prevalence of hemorrhoids globally escalates the need for hemorrhoid medications. The drugs used for the management of hemorrhoids include corticosteroids (hydrocortisone), topical anaesthetics (lidocaine), and antibiotics (doxycycline). The hemorrhoid treatment market is fueled by rising public awareness about gastrointestinal health and available treatments, leading to an increased demand for drugs for hemorrhoid treatment.

 Report Coverage

This research report categorizes the market for the global hemorrhoid drugs market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global hemorrhoid drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global hemorrhoid drugs market.

Driving Factors

A larger patient population, better diagnosis and treatment, and greater knowledge of the condition are all contributing factors to the growth of the worldwide hemorrhoid treatment market. Sedentary lifestyles, decreased fiber intake, and altered lifestyles significantly lead to improvements in medication, therapy, and medical equipment. Investments in infrastructure development in addition contribute to growth. The poverty of people, poor hygienic conditions, and sanitary conditions in middle-income countries expanding the market growth. The ease of use, and availability of hemorrhoid medications as over-the-counter drugs escalate the need for hemorrhoid treatment.

Restraining Factors

The availability of surgical tools and devices, social embarrassment during the treatment, presence of surgical procedures including infrared coagulation, and band ligation impede the market growth.

Market Segmentation

The global hemorrhoid drugs market share is classified into product type, drug class, and distribution channel.

• The creams and ointments held the largest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe.

Based on the product type, the global hemorrhoid drugs market is categorized into creams and ointments, suppositories, sprays, and others. Among these, the creams and ointments held the largest share in 2023 and is expected to grow at a significant CAGR during the projected timeframe. The segmental expansion has been accelerated by the rising global prevalence of the condition and patients' preference for using creams and ointments because of their accessibility, non-invasive symptom alleviation, and ease of application. Furthermore, it is anticipated that the use of these treatments to treat hemorrhoid symptoms will rise in conjunction with increased awareness campaigns concerning hemorrhoids.

• The corticosteroids segment accounted for the largest share in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe.

Based on the drug class, the global hemorrhoid drugs market is categorized into local anesthetics, non-steroidal anti-inflammatory drugs, corticosteroids, and others. Among these, the corticosteroids segment accounted for the largest share in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe. Corticosteroids, like hydrocortisone, come in a variety of forms, including suppositories and cream ointments. The process by which these corticosteroids relieve swelling, redness, and itching is by triggering natural substances in the skin. This helps to promote the use of corticosteroid treatments, which in turn boosts market growth.

• The drug stores and retail pharmacies held the largest share in 2023 and is predicted to grow at a remarkable CAGR during the projected period.

Based on the distribution channel, the global hemorrhoid drugs market is categorized as online pharmacies, drug stores and retail pharmacies, and hospital pharmacies. Among these, the drug stores and retail pharmacies held the largest share in 2023 and is predicted to grow at a remarkable CAGR during the projected period. The broad range of over-the-counter hemorrhoid products available and the growing patient inclination for self-treatment due to social stigma contribute to the segment's leading dominance. Moreover, the growing number of OTC product releases by major players is driving the segment expansion.

 Regional Segment Analysis of the Global Hemorrhoid Drugs Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global hemorrhoid drugs market over the predicted timeframe.

North America is anticipated to hold the largest share of the global hemorrhoid drugs market over the forecast period. This is attributed to government initiatives and schemes, the presence of statistical instruments and innovative and standard technologies, and the increasing prevalence of the hemorrhoid drugs market. Factors such as increasing disposable income, a growing patient base, and improved healthcare access will further propel market growth. Additionally, digital healthcare advancements and the rise of telemedicine consultations are making hemorrhoid treatments more accessible across the region.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is ascribed to the increasing proportion of FDA approvals and growth in research and development. The market growth is driven by an increasing prevalence of hemorrhoidal conditions, changing dietary habits, and rising awareness regarding treatment options. Countries like China, India, Japan, and South Korea are key contributors to market expansion due to their large populations and growing healthcare infrastructure.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global hemorrhoid drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lupin
• Sanofi
• Haleon Group of Companies
• Sun Pharmaceuticals,
• Bayer AG
• Abbott
• Cipla
• The Himalaya Drug Company 
• Panacea Biotec Ltd.
• Pfizer Inc.
• Purdue Parma L.P.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2023, Citius Pharmaceuticals announced the results of its Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for relief of hemorrhoid symptoms. The high-dose formulation significantly reduced symptom severity compared to individual components, with no significant adverse events. Citius plans to schedule an end-of-phase meeting with the FDA.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global hemorrhoid drugs market based on the below-mentioned segments:

Global Hemorrhoid Drugs Market, By Product Type

• Creams and Ointments
• Suppositories
• Sprays
• Others

Global Hemorrhoid Drugs Market, By Drug Class

• Local Anesthetics
• Non-Steroidal Anti-inflammatory Drugs
• Corticosteroids
• Others

Global Hemorrhoid Drugs Market, By Distribution Channel

• Online Pharmacies
• Drug Stores and Retail Pharmacy
• Hospital Pharmacies

Global Hemorrhoid Drugs Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East and Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East and Africa